Recombinant Human DR6 (C-Fc)

Description

EnkiLife provides the Recombinant Human DR6 (C-Fc) protein,aslo know as Tumor Necrosis Factor Receptor Superfamily Member 21,Death Receptor 6,CD358,TNFRSF21,DR6,UNQ437/PRO868, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Death Receptor 6 is produced by our Mammalian expression system and the target gene encoding Gln42-Leu350 is expressed with a human IgG1 Fc tag at the C-terminus.Accession:O75509. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:61.7 KDa. Background:Tumor Necrosis Factor Receptor Superfamily Member 21 (TNFRSF21) is a type I transmembrane receptor that includes four extracellular cysteine-rich motifs and a cytoplasmic death domain. DR6 is highly expressed in heart, brain, placenta, pancreas, lymph node, thymus and prostate. DR6 may activate NF-kappa-B and JNK to promote apoptosis and T-cell differentiation. In addition, DR6 binds with N-APP, which is released by the deprivation of Trophic-factor. It triggers caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6). DR6 is also expressed on the tumor cell lines and can be induced by TNF-α.